Inspire Medical Systems has surged nearly 15% since its breakout, driven by positive Q1 results and FDA approvals. Analysts have a "buy" rating on the stock.
Style Box ETF report for VTWO
The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action.
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.
Inspire (INSP) delivered earnings and revenue surprises of 24.29% and 6.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength...
Inspire (INSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
